Want to see SE:APOTEA full AI Analyst Report?
APOTEA Stock Chart & Stats
kr66.50
-kr0.22(-0.29%)
At close: 4:00 PM EST
kr66.50
-kr0.22(-0.29%)
Day’s Range― - ―
52-Week Rangekr54.42 - kr122.00
Previous CloseN/A
Volume107.34K
Average Volume (3M)136.78K
Market Cap
kr8.27B
Enterprise Valuekr7.92K
Total Cash (Recent Filing)kr103.50M
Total Debt (Recent Filing)kr279.30M
Price to Earnings (P/E)35.0
Beta0.44
Next Earnings
Nov 05, 2026EPS Estimate
0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.36
Shares Outstanding104,070,970
10 Day Avg. Volume129,131
30 Day Avg. Volume136,777
Financial Highlights & Ratios
PEG Ratio7.96
Price to Book (P/B)11.37
Price to Sales (P/S)1.33
P/FCF Ratio81.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.71
Revenue Forecast (FY)kr8.07B
Bulls Say, Bears Say
Bulls Say
Online Pharmacy ModelApotea's pure-play online pharmacy model aligns with structural consumer shifts to e-commerce for healthcare. A wide product assortment and focus on automated fulfillment support scale-driven unit cost reductions and repeat-purchase economics that persist over multi-month horizons.
Revenue & Profitability TrendReported revenue growth and improved profitability versus earlier years reflect operational execution and some operating leverage. Sustained top-line growth with stable operating margins suggests the business can incrementally convert scale into durable earnings improvement if trends continue.
Manageable LeverageCapital structure appears moderate with debt at about one-third of equity and a downward trend versus prior annual levels. Growing equity alongside assets provides a stronger buffer for cyclical stress and supports capacity for investment without immediate refinancing pressure.
Bears Say
Weak Cash ConversionA sharp decline in free cash flow and weak cash conversion relative to net income reduces financial flexibility. Persistent FCF volatility limits the firm's ability to fund growth, absorb shocks, or reliably return capital, making long-term planning and investment riskier.
Thin MarginsModest gross and operating margins leave limited buffer against cost inflation or pricing pressure. With operating profitability near 4%, the business lacks wide structural margin cushions, increasing sensitivity to logistics, input costs, or competitive price dynamics over the coming months.
Balance-sheet VariabilityLarge year-to-year step-changes reduce comparability and complicate forecasting of capital needs and returns. Uneven profitability on shareholder capital and episodic balance-sheet shifts undermine predictability, increasing execution and modelling risk for investors focused on fundamentals.
Apotea AB News
APOTEA FAQ
What was Apotea AB’s price range in the past 12 months?
Apotea AB lowest stock price was kr54.42 and its highest was kr122.00 in the past 12 months.
What is Apotea AB’s market cap?
Apotea AB’s market cap is kr8.27B.
When is Apotea AB’s upcoming earnings report date?
Apotea AB’s upcoming earnings report date is Nov 05, 2026 which is in 108 days.
How were Apotea AB’s earnings last quarter?
Apotea AB released its earnings results on Jul 17, 2026. The company reported kr0.79 earnings per share for the quarter, beating the consensus estimate of kr0.71 by kr0.08.
Is Apotea AB overvalued?
According to Wall Street analysts Apotea AB’s price is currently Overvalued.
Does Apotea AB pay dividends?
Apotea AB pays a N/A dividend of kr0.6 which represents an annual dividend yield of N/A. See more information on Apotea AB dividends here
What is Apotea AB’s EPS estimate?
Apotea AB’s EPS estimate is 0.71.
How many shares outstanding does Apotea AB have?
Apotea AB has 104,070,970 shares outstanding.
What happened to Apotea AB’s price movement after its last earnings report?
Apotea AB reported an EPS of kr0.79 in its last earnings report, beating expectations of kr0.71. Following the earnings report the stock price went up 7.87%.
Which hedge fund is a major shareholder of Apotea AB?
Currently, no hedge funds are holding shares in SE:APOTEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Apotea AB
Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, hair care, hands and feet, intimate, and dietary supplements. It also provides products in the categories of body care, stomach and intestine, food and drink, mouth and teeth, premium, trip, sex and lust, stop smoking, makeup, sun protection, wounds and injuries, sleep and sleep problems, training, weight control, vitamins and minerals, charity, and eyes and ears. In addition, the company offers services comprising leasing, leasing of personnel to related companies. and market contributions. The company was founded in 2011 and is headquartered in Stockholm, Sweden.